Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.90
- Piotroski Score 6.00
- Grade Buy
- Symbol (AAIC)
- Company Arlington Asset Investment Corp.
- Price $4.84
- Changes Percentage (1.47%)
- Change $0.07
- Day Low $4.69
- Day High $4.84
- Year High $4.84
Arlington Asset Investment Corp. (NYSE: AAIC) currently invests primarily in mortgage-related and other assets and has elected to be taxed as a REIT. The Company is headquartered in the Washington, D.C. metropolitan area. For more information, please visit www.arlingtonasset.com.
- Last Earnings 12/13/2019
- Ex-Dividend for 5/16 Dividend 12/30/2019
- Dividend Payable 02/03/2020
- Today N/A
- Next Earnings (Estimated) 11/12/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.08
- Trailing P/E Ratio -60.5
- Forward P/E Ratio -60.5
- P/E Growth -60.5
- Net Income $5.43 M
Income Statement
Quarterly
Annual
Latest News of AAIC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
AAIC 2024: MCI patient reflects on Leqembi trial experience
Ralph Carmona shared his journey of being diagnosed with Mild Cognitive Impairment (MCI) due to Alzheimer's at the 2024 AAIC session. He participated in a clinical trial for Leqembi, despite recent co...
By Yahoo! Finance | 3 months ago -
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)
Longeveron Inc. presents promising Phase 2a clinical trial data on Lomecel-B™ at the AAIC 2024, showing improvements in cognitive function and brain volume in mild Alzheimer's Disease. The therapy d...
By Yahoo! Finance | 3 months ago
